A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation

Neuroscience

Volumn 117, Issue 3, 2003, Pages 659-670

  Nackley, A G ^a   Suplita II, R L ^a   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

Author keywords

Anandamide; Dorsal horn; Endocannabinoid; Inflammation; Von Frey

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; CARRAGEENAN; PROTEIN FOS; RIMONABANT;

ALLODYNIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ENANTIOMER; HYPERALGESIA; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MALE; MOLECULAR BIOLOGY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SPINAL CORD DORSAL HORN;

EID: 0037475146     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00870-9     Document Type: Article

References (58)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
2. Beaulieu P., Bisogno T., Punwar S., et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol. 396:2000;85-92.
3. Buritova J., Chapman V., Honore P., Besson J.M. The contribution of peripheral bradykinin B2 receptors to carrageenan- evoked oedema and spinal c-Fos expression in rats. Eur J Pharmacol. 320:1997;73-80.
4. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
5. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53:1994;55-63.
6. Compton D.R., Gold L.H., Ward S.J., Balster R.L., Martin B.R. Aminoalkylindole analogs cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol . J Pharmacol Exp Ther. 263:1992;1118-1126.
7. Drew L.J., Harris J., Millns P.J., Kendall D.A., Chapman V. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci. 12:2000;2079-2086.
8. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 92:1995;3376-3380.
9. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513.
10. Farquhar-Smith W.P., Jaggar S.I., Rice A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. 97:2002;11-21.
11. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-450.
12. Greenhouse S.W., Geisser S. On methods in the analysis of profile data. Psychometrika. 24:1959;95-112.
13. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., Fride E. HU-308 a specific agonist for CB(2), a peripheral cannabinoid receptor . Proc Natl Acad Sci USA. 96:1999;14228-14233.
14. Harris J., Drew L.J., Chapman V. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport. 11:2000;2817-2819.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain a quantitative in vitro autoradiographic study . J Neurosci. 11:1991;563-583.
16. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160.
17. Hohmann AG (2002) Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids, 121:173-190.
18. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
19. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia a double-label in situ hybridization study . Neuroscience. 90:1999;923-931.
20. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, 212-2. Life Sci. 56:1995;2111-2118.
21. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci Lett. 257:1998;119-122.
22. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophys. 81:1999;575-583.
23. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord comparison with morphine . Acta Pharmacologica Sinica. 20:1999;1132-1136.
24. Honore P., Buritova J., Besson J.M. Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat. Br J Pharmacol. 118:1996;671-680.
25. Honore P., Catheline G., Le Guen S., Besson J.M. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats. Pain. 71:1997;99-108.
26. Honore P., Chapman V., Buritova J., Besson J.M. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Brain Res. 705:1995;91-96.
27. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabeled antibody (PAP) procedures . J Histochem Cytochem. 29:1981;577-580.
28. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
29. Iadarola M.J., Brady L.S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation stimulus specificity, behavioral parameters and opioid receptor binding . Pain. 35:1988;313-326.
30. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain. 93:2001;303-315.
31. Joris J., Costello A., Dubner R., Hargreaves K.M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain. 43:1990;95-103.
32. Kelly S., Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol. 86:2001;3061-3064.
33. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys a peripheral cannabinoid action . Psychopharmacology (Berl). 143:1999;322-326.
34. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat implications for receptor-mediated immune modulation by cannabinoids . J Pharmacol Exp Ther. 268:1994;1612-1623.
35. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA. 89:1992;3825-3829.
36. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. Neuroscience. 15:1995;6552-6561.
37. 2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
38. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist correlation between electrophysiological and antinociceptive effects . J Neurosci. 16:1996;6601-6611.
39. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
40. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
41. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 300:1996;227-236.
42. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
43. Noguchi K., Dubner R., Ruda M.A. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience. 46:1992;561-570.
44. Noguchi K., Kowalski K., Traub R., Solodkin A., Iadarola M.J., Ruda M.A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res Mol Brain Res. 10:1991;227-233.
45. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1998;Academic Press, San Diego.
46. Presley R.W., Menetrey D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J Neurosci. 10:1990;323-335.
47. 1 receptors. Pain. 75:1998;111-119.
48. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
49. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 284:1998;644-650.
50. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., MacEwan D.J., Scott R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones implications for antinociception . Neuropharmacology. 40:2001;221-232.
51. Simone D.A., Seybold V.S. Cannabinoids worthwhile analgesics? J Pain. 1:2000;18-19.
52. Strangman N.M., Patrick S.L., Hohmann A.G., Tsou K., Walker J.M. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 813:1998;323-328.
53. Strangman N.M., Walker J.M. Cannabinoid WIN 55, 212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol. 82:1999;472-477.
54. Tsou K., Brown S., Sanudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
55. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
56. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol. 280:1995;R13-15.
57. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 96:1999;5780-5785.
58. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.